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Aims: In animals, intracerebroventricular glucose and fructose have opposing effects on appetite and weight regulation. In humans, functional
brain magnetic resonance imaging (fMRI) studies during glucose ingestion or infusion have demonstrated suppression of hypothalamic
signalling, but no studies have compared the effects of glucose and fructose. We therefore sought to determine if the brain response differed
to glucose vs. fructose in humans independently of the ingestive process.
Methods: Nine healthy, normal weight subjects underwent blood oxygenation level dependent (BOLD) fMRI measurements during either
intravenous (IV) glucose (0.3 mg/kg), fructose (0.3 mg/kg) or saline, administered over 2 min in a randomized, double-blind, crossover study.
Blood was sampled every 5 min during a baseline period and following infusion for 60 min in total for glucose, fructose, lactate and insulin
levels.
Results: No signiﬁcant brain BOLD signal changes were detected in response to IV saline. BOLD signal in the cortical control areas increased
during glucose infusion (p = 0.002), corresponding with increased plasma glucose and insulin levels. In contrast, BOLD signal decreased in the
cortical control areas during fructose infusion (p = 0.006), corresponding with increases of plasma fructose and lactate. Neither glucose nor
fructose infusions signiﬁcantly altered BOLD signal in the hypothalamus.
Conclusion: In normal weight humans, cortical responses as assessed by BOLD fMRI to infused glucose are opposite to those of fructose.
Differential brain responses to these sugars and their metabolites may provide insight into the neurologic basis for dysregulation of food intake
during high dietary fructose intake.
Keywords: appetite control, glucose metabolism, neuropharmacology
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Introduction
Hypothalamic centres have been shown to control food
intake and energy expenditure in response to changes in
glucose levels [1]. Earlier work in this area focused on how
hypoglycemia affects hypothalamic neuronal activity with sub-
sequent elucidation of neuronal responses to changes in glucose
levels that fall within the physiological range [1,2]. Two dis-
tinct populations of neurons in the hypothalamus have been
described that respond oppositely to rising glucose levels: those
that are glucose-inhibited (or glucose-sensitive) and decrease
their activity, and those that are glucose-excited (or glucose-
responsive) and increase their electrical firing rates [1,3]. In
the ventromedial hypothalamus (VMH, including both the
arcuate and ventromedial nuclei), it has been estimated that
Correspondence to: Dr. Jonathan Q. Purnell, Division of Endocrinology, Diabetes, and
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∼30% of the neurons respond to changes in glucose concentra-
tions with approximately two-thirds that are glucose-excited
and one-third that are glucose-inhibited [1,3]. Glucose-sensing
neurons are also located in the lateral and paraventricular neu-
rons of the hypothalamus, which have extensive intra-nuclei
connections between each other and the VMH [4]. These find-
ings have led to current hypotheses that these glucose-sensing
neurons in the hypothalamus play an integrating role in the
brain’s ability to maintain energy homeostasis [4–6].
Fructose is also another dietary carbohydrate with central
effects that has been implicated in body weight regulation in
animal models and humans [7–9]. The fructose-specific trans-
porter, GLUT5, is found in microglia of the hippocampus and
cortex [10] as well as Purkinje cells of the cerebellum [11], and
the GLUT2 receptor, which has a low affinity for fructose, has
been found in hypothalamic tanycytes [12]. A recent study in
rodents demonstrated that an intracerebroventricular (ICV)
injection of fructose had opposite effects to an injection of
glucose on hypothalamic metabolism and food intake [13].
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Studying brain function in humans has been advanced
by non-invasive neuroimaging technology. Functional brain
magnetic resonance imaging (fMRI) is one such technique
that detects changes in regional brain blood flow and concen-
trations of deoxygenated haemoglobin (abbreviated as blood
oxygenation level dependent, or BOLD, signal) in response to a
stimulus (i.e. viewing pictures, listening to sounds and perform-
ing a task) as a surrogate measure of neuronal activity [14,15].
Previous studies have explored the temporal response to glu-
cose ingestion or infusion using fMRI and found suppression of
hypothalamic BOLD signalling after administration of glucose
to rats [16] and humans [17–20]. Obese subjects were found to
have diminished attenuation of the BOLD signal suppression
to glucose ingestion compared with lean subjects [21], and
patients with type 2 diabetes have shown to show no hypotha-
lamic signal change compared with non-diabetic patients [19].
No studies to date have, however, compared the brain BOLD
response of glucose to fructose in humans. Thus, we hypothe-
sized that the change in hypothalamic BOLD signal to glucose
would be different from fructose in magnitude, direction or
both. As study conditions, we chose to administer the carbo-
hydrate boluses intravenously (IV) to avoid potentially con-
founding effects on the brain and hypothalamic BOLD response
from neuronal responses to taste [22] or changes in levels of
gut hormones [23], and included a control injection of saline.
Materials and Methods
Research Subjects
Nine healthy subjects (6 women, 3 men) with a mean ± stan-
dard deviation age of 29 ± 4.3 years and body mass index of
22.0 ± 2.2 kg/m2 were recruited using posted advertisements.
Subjects were enrolled if they were at their maximal lifetime
weight, had been weight stable for at least 3-months, were free of
known medical illness, non-smokers, and not taking prescrip-
tion medications and had no contraindication to exposure to
strong magnetic fields. At the time of the screening visit, study
participants met with a Bionutritionist of the Oregon Clinical
and Translational Research Institute to review their current
dietary intake. Subjects were enrolled if they were consuming
a diet that approximated the typical American macronutrient
intake (∼35% of total calories as fat, 15% as protein and 50%
as carbohydrates) and agreed to continue to do so during the
duration of the study. Exclusionary criteria included abnormal
renal or liver function tests, or elevated uric or lactic acid levels.
The Oregon Health & Science University (OHSU) Investiga-
tional Review Board approved all procedures, and informed
consent was obtained before study entry.
Study Design
Enrolled subjects returned on three separate visits to the OHSU
Advanced Imaging Research Center. At each visit, following an
overnight fast at approximately 8:00 A.M., an IV catheter was
placed into a vein in each arm and subjects underwent a 60-min
fMRI scan to measure BOLD response. This scan consisted of
an initial baseline 10-min period after which an infusion of
glucose (0.3 mg/kg), fructose (0.3 mg/kg) or saline was given
over 2 min. Typical infusion volumes using 50% concentration
solutions for both glucose and fructose to administer roughly
20–25 g of carbohydrate typically ranged between 40 and
50 ml. Scanning continued during the infusion and for another
50 min. During the entire 60-min period, blood was collected
every 5 min into heparinized tubes for separation of plasma
and measurements of glucose and insulin (all three scans) and
lactate (glucose and fructose scans only) and fructose (fructose
scan only). The IV infusion and blood draws were performed
by a nurse in the scanner suite. The scans were separated by at
least 1 week and the infusion order was randomized.
Imaging Protocol
Images were acquired using a Siemens Magnetom Trio 3-Tesla
(Siemens Medical Solutions, Malvern, PA, USA and Erlangen,
Germany) whole body system. Subjects were positioned inside
the bore of the magnet supine with their heads immobilized
using cushions within a head coil. For each subject, T1-weighted
three-dimensional high-resolution anatomic images (Sagittal
MPRAGE repetition time: 2300 ms, echo time: 4.38 ms, flip
angle: 12◦, Slices: 144, FOV: 256 × 208, in-plane spatial
resolution: 0.938 mm × 0.938 mm × 1 mm) were acquired
for accurate anatomical localization of the hypothalamus
(figure 1). Following this, a conventional T2-weighted gradient
echo MRI pulse sequence was used for BOLD measurement
(echo time: 32 ms; repetition time: 72 ms; flip angle: 20◦; two
contiguous mid-sagittal slices; FOV: 200; matrix 192 × 100;
in-plane spatial resolution: 1 mm× 1 mm × 5 mm). These
acquisition parameters were used to attempt to limit the
artefact arising from the proximity of the hypothalamus to
Figure 1. Upper panels: anatomic images depicting brain slice prescrip-
tion for the functional data acquisition. Two slices (orange overlay) were
acquired, each 1 × 1 × 5 mm on either side of midline. Lower panel:
hypothalamic region of interest (ROI) (orange overlay) as hand drawn in
a single subject.
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the sinus cavity, which can introduce signal inhomogeneities
into surrounding tissue. A total of 440 volumes were acquired
during the 60-min scan.
Image Analysis
Following scan completion, all images underwent similar
processing before analysis, including motion correction in
two dimensions and linear detrending. The signal intensity
was normalized using a z-score transformation, such that
the average signal intensity was set equal to 0 and the
standard deviation set equal to 1. Each functional scan was
co-registered to the MPRAGE for anatomic localization and
a single technician drew the hypothalamic region of interest
(ROI) for comparison with the cortical control areas (figure 1)
according to anatomic landmarks previously published [21].
Voxels that partially fell outside of the hypothalamus were
manually removed before final analysis to reduce partial
volume effects on the data. The hypothalamic ROI sizes for
all subjects ranged between 110 and 176 voxels. Initially, the
hypothalamus was separated into anterior and posterior, upper
and lower segments [21], to determine if there were absolute or
temporal differences in fMRI signal responses to the infusions
in these regions. When no signal response differences were
demonstrated, the regions were combined to increase power for
final analysis. Each voxel time series was extracted and averaged
on a voxel-wise basis. Initially, ten 10 × 10 mm2 cortical regions
outside the hypothalamus were chosen for control areas,
including the motor cortex as previously studied [17]. When
all cortical sites demonstrated a similar BOLD response during
each infusion, they were combined to form a non-hypothalamic
cortical control region so as to increase statistical power. The
baseline period was defined as the 5 min preceding IV infusion.
Subsequent voxel time series were collapsed into 5-min bins for
statistical comparisons of percent signal change from baseline
in the hypothalamic ROI and cortical control areas.
Assays
Glucose, Insulin, and Lactate. Glucose and lactate were
measured with a YSI Model 2300 analyser (Yellow Springs, OH,
USA). Fasting plasma insulin concentrations were measured
with a chemiluminescent immunoassay using the automated
immulite system (Siemens Healthcare Diagnostics, Deerfield,
IL, USA). This method has an analytical sensitivity of 13.9
pmol/l and an inter-assay COV of 6.4%.
Plasma Fructose. Plasma fructose concentrations were deter-
mined using a modification of a commercial glucose/fructose
analytical kit (Megazyme, catalog item K-FRUGL; Xygen
Diagnostics, Burgessville, Ontario, Canada) as previously
described [24]. Reduced NADP (NADPH) absorbance was
measured at 340 nm as a measure of sample glucose concentra-
tion (NADPH generation from glucose-6-phosphate reaction
with G6PDH). Following this, phosphoglucoisomerase (PGI)
was added to each well and NADPH absorbance was again
measured (PGI converts fructose-6-phosphate to glucose-6-
phosphate, with NADPH generation via G6PDH). The change
in absorbance from the previous reading was used to deter-
mine fructose concentration from a standard curve. To account
for matrix effects, fructose standards were diluted in an
EDTA-plasma matrix (plasma from overnight-fasted human
subjects containing no detectable fructose).
Statistics
Glucose, fructose, insulin and lactate levels are reported as
mean concentration ± standard error of the mean, and paired
t-tests were performed to determine statistical significance in
concentration after infusion compared with baseline. Statistical
significance was defined by two-tailed p value <0.05. The
observed haemodynamic signal changes in hypothalamus and
control cortical areas were analysed separately using two-factor
(3 × 9) repeated measures analysis of variance, with infusion
(saline, fructose and glucose) and time (nine time bins) as the
within-subjects factors. Post hoc comparisons were conducted
using paired t-tests.
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Figure 2. (A) Glucose levels and (B) insulin levels following infusion
of glucose (closed circles), fructose scan (open circles) and saline scan
(closed triangles) in normal weight adults. Base: 5-min baseline period.
Inf: 5-min period including 2-min period of infusion. Results are mean
± standard error. Glucose levels RMANOVA (glucose, fructose, saline):
F(2.7, 15.0) = 19.4, p < 0.001. Insulin levels RMANOVA (glucose, fructose,
saline): F(3.9, 21.2) = 6.7, p = 0.001. ∗p < 0.05, †p < 0.001, ‡p < 0.01,
§p = 0.001 compared with baseline by paired t-test.
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Figure 3. Levels of fructose and lactate following infusion of glucose
and fructose in normal weight adults. Base: 5-min baseline period. Inf:
5-min period including 2-min period of infusion. Results are mean
± standard error. Fructose levels RMANOVA F(8, 24) = 90.0, p < 0.001.
Lactate levels RMANOVA (glucose, fructose) F(8, 48) = 8.0, p < 0.001.
∗p < 0.05, †p < 0.001, ‡p < 0.01, §p = 0.001 compared with baseline
by paired t-test.
Results
Plasma Glucose, Insulin, Fructose and Lactate
Concentrations
During the saline infusion scans, plasma glucose and insulin
concentrations remained close to baseline, although glucose
levels drifted slightly upwards (p < 0.05) towards the end of the
scanning period (figure 2). During the glucose infusion scans,
both plasma glucose and insulin concentrations significantly
increased, achieving peak levels of ∼14 and ∼400 pmol/l,
respectively within the first 5 min (figure 2). Plasma lactate
levels also increased progressively from baseline after a delay
of ∼10 min after the glucose infusion (p < 0.05 to <0.01
compared with baseline; figure 3); whereas plasma insulin and
glucose concentrations returned to baseline (figure 2). During
the fructose infusion scans, plasma fructose levels increased
in similar pattern as glucose did during the glucose infusion,
from undetectable levels to a peak of ∼8 mmol/l with in
the first 5 min (p < 0.05 to <0.001 compared with baseline;
figure 3). Following the fructose infusion, plasma lactate levels
significantly increased, peaking at 0.5 mmol/l 15 min after the
infusion (figure 3) and glucose levels increased significantly
∼20–25 min after the infusion (p < 0.05 compared with
baseline; figure 2). Plasma insulin concentrations also increased
(p < 0.05 compared with baseline) to ∼150 pmol/l, beginning
soon after the fructose infusion (figure 2) but remained
substantially smaller than those observed after glucose infusion.
fMRI BOLD Signal Change in Response to Infusions
of Saline, Glucose and Fructose
During the saline infusion, BOLD signal response across time
in both the hypothalamus and brain cortical control regions
did not vary significantly from baseline (figure 4). The BOLD
responses in the cortical control regions differed significantly
during the glucose, fructose and saline infusions [F(4.3, 45.7) =
9.1, p < 0.001] by three-way repeated measures analysis of vari-
ance (figure 4). In response to the glucose infusion, fMRI signal
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Figure 4. Percent functional magnetic resonance (fMRI) signal change
in hypothalamus (A) and brain control regions (B) in response to a
saline (closed triangles), glucose (closed boxes) and fructose infusions
(open circles) in normal weight adults. Base: 5-min baseline period.
Inf: 5-min period including 2-min period of infusion. Results are mean
± standard error. RMANOVA (glucose, fructose, saline): hypothalamus
F(6.4, 67.0) = 0.52, p = 0.80, brain control regions [F(4.3, 45.7) = 9.1,
p < 0.001]. ∗p < 0.05, †p < 0.01 compared with baseline by paired t-test.
in the cortical control regions increased significantly above
baseline beginning with the infusion period and remained
elevated for the next 20 min [RMANOVA glucose vs. saline:
F(3.1, 40.8) = 5.6, p = 0.002]. In contrast, during the fructose
infusion BOLD signal decreased in the cortical control regions,
also beginning shortly after infusion and remained depressed
for 20 min [RMANOVA fructose vs. saline: F(1.8, 27.1) = 6.6,
p = 0.006]. The changes in BOLD signal in the hypothalamic
ROI paralleled the cortical brain responses but did not achieve
statistical significance at any binned period compared with
baseline or when comparing between carbohydrate and saline
infusions [three-way RMANOVA F(6.4, 67.0) = 0.52, p = 0.80].
Safety
During the glucose infusion subjects most commonly reported
a feeling of warmth, a ‘sweet’ taste in their mouth, or an urgency
to urinate lasting only a few seconds. During the fructose
infusions, subjects most commonly reported feeling cold, chest
tightness or shortness of breath lasting a few minutes, but none
noted a ‘sweet’ taste. No subject stopped their scan because of
these effects. No blood lactate level exceeded 2.0 mmol/l during
the fructose infusion, a predetermined safety cut-off level.
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Discussion
We undertook the present studies to determine if changes
in hypothalamic fMRI BOLD signal were different during a
glucose infusion compared with a fructose infusion. Our study
design included double-blind, randomized, crossover scanning
sessions on different days that included an isovolemic infusion
of saline as a control condition. We used a similar fMRI
image acquisition method as previously published [17,21],
including a narrow slice prescription through the midline
to increase the sensitivity of detecting signalling changes in the
hypothalamus. We further increased our sensitivity to detect
hypothalamic BOLD signal changes by individually defining
the hypothalamic ROI using each subject’s anatomical scans
and excluding non-brain regions from analysis.
Contrary to the expected reduction in hypothalamic BOLD
signal based on previous glucose ingestion studies [17,21],
we found that no significant changes in hypothalamic BOLD
signal were detected during glucose infusion. Our finding is also
in contrast to a recent study comparing hypothalamic BOLD
response of oral to IV glucose by Smeets et al. in seven men [20].
In that study, which used a similar imaging protocol and
hypothalamic anatomic landmarks to ours, the hypothalamic
BOLD response to IV glucose was greatly attenuated (<1%
difference compared with baseline) as compared to the
suppression following glucose ingestion. Several notable
differences between the studies, however, may explain these
discrepant findings. In addition to studying a larger group of
subjects that included both women and men, as opposed to just
men, subjects in the present study also received a lower infusion
dose of glucose (0.3 vs. 0.5 mg/kg). This dose was chosen
because it is standard for insulin sensitivity testing [25], but
may have resulted in further attenuation of the hypothalamic
signal. On the other hand, it is unlikely that our data represent
an absence of glucose responsiveness in the hypothalamus in
humans. Rather, the hypothalamic BOLD signal during glucose
could represent a confluence of both stimulatory and inhibitory
neurons that, being in close proximity [1], cancelled each other
out leading to a net signal change that was not significantly
different from baseline. Alternatively, increases of circulating
insulin and/or lactate concentrations, both of which have been
shown to increase hypothalamic neuronal signalling [3], may
have counteracted effects on predominantly glucose-inhibited
neurons in this area. In any event, our data suggest that increases
in levels of glucose and insulin are not the primary factors
causing suppression of hypothalamic BOLD signal previously
reported after glucose ingestion.
Comparison of BOLD response to IV fructose was under-
taken because of recent studies linking high fructose con-
sumption with weight gain, obesity and components of the
metabolic syndrome [7–9,26]. Fructose given ICV to rats [7]
and mice [13] increases food intake, an effect opposite to ICV
glucose, which suppresses food intake. A high fructose diet
increased body adiposity in mice [9], and studies in humans
have shown that consumption of fructose-sweetened beverages
increase subjective hunger ratings and ad libitum consumption
of fat the following day [27]. Including an imaging session dur-
ing an isovolemic, isocaloric fructose infusion also allowed us
to compare the effects on BOLD response during IV glucose to
a similar osmotic load of another simple carbohydrate. Despite
evidence for rapid uptake, metabolism and changes in cellular
response to a site-specific hypothalamic injection of fructose in
rodents [13,28], we found no significant change in hypothala-
mic BOLD signal change to IV fructose. Similar to the glucose
infusion results, this finding could represent a composite signal
generated by competing stimulatory effects, such as increases
in peripheral and intrahypothalamic lactate levels [3,28] vs.
potentially inhibitory effects mediated by induction of insulin
resistance and reduced intra-neuronal insulin signalling [29],
or as a result of the fact that fructose has a higher fractional
extraction rate in the liver where initially higher concentrations
could activate vagal afferents that might impact signalling in
higher brain regions [30].
In contrast to the hypothalamic findings, we detected
marked differences in cortical BOLD signal changes between
the glucose and fructose infusion studies: a decrease during
the fructose infusion compared with an increase during the
glucose infusion. Although our subjects frequently experienced
a flushing sensation during the glucose infusion, suggesting a
vasodilatory response that might explain an increase in cortical
BOLD signal, this sensation lasted only a few seconds on
average (compared to the nearly 20 min sustained increase
in cortical BOLD signal) and data from animal studies
have shown that acute hyperglycemia or increased osmolality
results in temporarily decreased, not increased, cerebral blood
flow [31–33]. As for the net suppressive effect of fructose
on cortical BOLD signal, this occurred despite the fact
that fructose-specific receptors (GLUT5) are present in low
concentrations throughout the brain [10,11,34], where the
glucose transporter GLUT3 predominates [1]. Whether this
cortical response to fructose is due to effects mediated by
GLUT2 and GLUT5 carriers in the blood–brain barrier [34] or
in local glia cells [10], due to increased osmolality [33], or is the
indirect result of changes in levels of peripheral neural input or
metabolic intermediaries which will require further study.
In summary, we found that glucose and fructose infusions in
lower concentrations than previously given significantly stim-
ulated and inhibited, respectively, net BOLD signal in cortical
control regions but did not significantly alter hypothalamic
BOLD signal. Frequent blood sampling during each infusion
revealed appearances of additional hormones and metabolic
products that could have contributed to these differential
changes in the cortical signal, and potentially confounded the
ability to detect significant signal changes in the hypothalamus.
Nevertheless, the differences we report in brain responses to
glucose and fructose infusions in these normal weight subjects
are supportive of a neurological basis for the recently demon-
strated effect of dietary fructose to promote weight gain in
animals [9] and a preference for consumption of higher fat
foods in humans [27].
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